Aytu BioScience (AYTU) –
-
Aytu BioScience (AYTU) Misses Q2 EPS by 4c
-
Form 8-K AYTU BIOPHARMA, INC For: Feb 14
-
Form 10-Q AYTU BIOPHARMA, INC For: Dec 31
-
Aytu BioPharma Reports Record ADHD Revenue and Operating Income During Fiscal 2024 Second Quarter
-
Form SC 13G/A AYTU BIOPHARMA, INC Filed by: Stonepine Capital Management, LLC
-
Aytu BioPharma to Report Second Quarter Fiscal 2024 Financial and Operational Results on February 14, 2024
-
Aytu BioPharma to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024
-
Form 4 AYTU BIOPHARMA, INC For: Dec 31 Filed by: PYSZCZYMUKA GREG
-
Presenting on the Emerging Growth Conference 65 Day 2 on December 7th Register Now
-
Aytu BioPharma to Present on the Emerging Growth Conference on December 7, 2023
-
Form 8-K AYTU BIOPHARMA, INC For: Nov 13
-
Form 8-K AYTU BIOPHARMA, INC For: Nov 14
-
Form 10-Q AYTU BIOPHARMA, INC For: Sep 30
-
Aytu BioScience (AYTU) Reports Q1 Revenue of $22.1M, Net Loss of $8.1M
-
Aytu BioPharma Reports Fiscal 2024 First Quarter Financial Results
-
Aytu BioPharma Ranked Among Fastest-Growing Companies in North America on Deloitte's Technology Fast 500(TM) for Third Consecutive Year
-
Aytu BioPharma to Report First Quarter Fiscal 2024 Financial Results on November 14, 2023
-
Form 8-K AYTU BIOPHARMA, INC For: Oct 25
-
Aytu BioScience (AYTU) Announces Approval of the Cotempla XR-ODT(R) Manufacturing Site Transfer Prior Approval Supplement
-
Aytu BioPharma Announces Approval of the Cotempla XR-ODT(R) Manufacturing Site Transfer Prior Approval Supplement
-
Form 10-K AYTU BIOPHARMA, INC For: Jun 30
-
Aytu BioPharma to Present at Lytham Partners Fall 2023 Investor Conference on October 17, 2023
-
Aytu BioScience (AYTU) Announces COO Departure
-
Form 8-K AYTU BIOPHARMA, INC For: Oct 03
-
Form 4 AYTU BIOPHARMA, INC For: Sep 30 Filed by: PYSZCZYMUKA GREG
-
Form NT 10-K AYTU BIOPHARMA, INC For: Jun 30
-
Aytu BioScience (AYTU) Reports Q3
-
Form 8-K AYTU BIOPHARMA, INC For: Sep 27
-
Aytu BioPharma Reports Record Revenues, Record Prescriptions, and Highest Adjusted EBITDA in Company History for the Fourth Quarter of Fiscal Year 2023
-
Aytu BioPharma to Report Fourth Quarter and Fiscal 2023 Financial Results on September 27, 2023
-
Aytu BioPharma to Present at LD Micro Main Event XVI Conference
-
Form 4 AYTU BIOPHARMA, INC For: Aug 16 Filed by: JAIN ABHINAV
-
Form 4 AYTU BIOPHARMA, INC For: Aug 11 Filed by: Disbrow Jarrett
-
Form 4 AYTU BIOPHARMA, INC For: Aug 11 Filed by: JAIN ABHINAV
-
Form 4 AYTU BIOPHARMA, INC For: Aug 11 Filed by: LIU VIVIAN H
-
Form 4 AYTU BIOPHARMA, INC For: Aug 11 Filed by: Donofrio John Jr.
-
Form 4 AYTU BIOPHARMA, INC For: Aug 11 Filed by: DOCKERY CARL
-
Form 4 AYTU BIOPHARMA, INC For: Aug 11 Filed by: Disbrow Joshua R.
-
Form 4 AYTU BIOPHARMA, INC For: Aug 11 Filed by: BROOKE CHRISTOPHER
-
Form 4 AYTU BIOPHARMA, INC For: Aug 11 Filed by: Oki Mark K
-
Form 4 AYTU BIOPHARMA, INC For: Aug 11 Filed by: PYSZCZYMUKA GREG
-
Form 8-K AYTU BIOPHARMA, INC For: Aug 11
-
Stonegate Capital Partners Announces Publishing of a Thematic Report - Undervalued Growth Pharma Companies Amidst Healthcare Sector Decline
-
Maxim Group Starts Aytu Biosciences (AYTU) at Buy
-
Form 8-K AYTU BIOPHARMA, INC For: Jul 31
-
Aytu BioScience (AYTU) Enters Agreement with Medomie Pharma to Commercialize Adzenys XR-ODT and Cotempla XR-ODT in Israel and Palestine
-
Aytu BioPharma Announces Exclusive Agreement with Medomie Pharma Ltd. to Commercialize Adzenys XR-ODT(R) and Cotempla XR-ODT(R) in Israel and the Palestinian Authority
-
Form 8-K AYTU BIOPHARMA, INC For: Jul 10
-
Aytu BioScience (AYTU) Announces Submission of Cotempla XR-ODT Manufacturing Site Transfer Prior Approval Supplement
-
Aytu BioPharma Announces Submission of Cotempla XR-ODT(R) Manufacturing Site Transfer Prior Approval Supplement
Back to AYTU Stock Lookup